FIRST Project

ADNUCLEIS is the winner of the “Resilience” call for tenders launched in 2020 by Bruno Le Maire, Minister of the Economy, Finance and Recovery

In this respect, the PCR First project of ADNucleis aims at the sovereignty of our State in the field of health, through the creation of a French sector of real-time PCR diagnostic products (DM DIV) intended to provide for the structural deficits, first and foremost the reagents, In order to be resilient and in response to government incentives,

ADNucleis will have the capacity to produce several million reagents per year with a minimum stock of reagents one year after creation. These diagnostic kits will be made available to our country as a priority in case of a desire for mass screening in one or more regions, at a price much lower than the prices charged since February 2020.


ADNucleis is carrying out its industrial transformation with private and academic institutions and is continuing its activity in the creation of PCR kits, particularly targeting the respiratory sphere (COVID, GRIPPE, RSV or respiratory syncitial virus, Bordetella responsible for whooping cough) with 4 diagnostic kits for Sars Cov2, accepted by the ANSM, CE marked.

The company is firmly committed to the fight against the virus.

The company is also at the origin of the manufacture of PCR robots allowing unqualified personnel to carry out, without external intervention and without manipulation, DNA or RNA extraction, and gene amplification or PCR itself

Pr Michel Franck

PDG Adnucleis